



NEWS RELEASE

7 September 2006

GROPEP LAUNCHES NEW PRODUCT TO SUPPORT CELL CULTURE PRODUCTS BUSINESS

Listed biopharmaceutical company GroPep Limited (ASX: GRO) today announced the launch of a new assay kit as part of its Cell Culture Products business. The kit provides a faster and more accurate way to measure LONGTMR³IGF-I, GroPep's growth factor supplement for the industrial manufacture of biopharmaceuticals.

The assay kit will support customer use and adoption of GroPep's leading product LONGTMR³IGF-I, an analogue of insulin-like growth factor I – currently used in the manufacture of 7 internationally approved biopharmaceuticals that generated annual sales in excess of US\$4.2 billion in 2005-06.

GroPep's new kit will help customers meet regulatory requirements by making it easier to reliably measure LONGTMR³IGF-I in their manufacturing processes.

Mr Greg Moss-Smith, VP Commercial Operations said "the speed and reliability of the kit is a substantial improvement over what was previously available and will help customers who need to make frequent and accurate measurements of LONGTMR³IGF-I to comply with biopharmaceutical manufacturing standards."

The new assay kit has been developed under GroPep's joint venture arrangement with ImmunoDiagnostic Systems Ltd (IDS, Boldon, UK). Under the agreement GroPep develops, produces and supplies antibodies and antigens to IDS who develop and manufacture assay kits. The companies share the marketing rights for the kits manufactured and sold under the agreement.

About GroPep

GroPep is a world leader in the development, manufacture and commercialisation of biologically active proteins for cell culture and biomedical research. The Company has an active biopharmaceutical development program that establishes proof of concept for products in humans and partners the later stages of product development and marketing with major pharmaceutical companies. GroPep is listed on the Australian Stock Exchange Limited (ASX code: GRO).

About IDS

IDS specialises in developing and marketing immunoassay kits and have an impressive product range in the areas of bone and mineral metabolism, cytokine and adhesion molecules, diabetes, growth factors, growth regulation and endocrinology.

Further Information:

Mr Tony Mitchell
Chief Financial Officer/Investor Relations
investorrelations@gropep.com.au

Ph: 08 8354 7700

GroPep Limited

ABN 78 008 176 298

28 Dalgleish Street

Thebarton SA 5031

PO Box 10065 BC

Adelaide SA 5000

Australia

Ph (61 8) 8354 7700

Fax (61 8) 8354 7788

Website

www.gropep.com.au